ID

43679

Descrizione

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02226276

collegamento

https://clinicaltrials.gov/show/NCT02226276

Keywords

versioni (2)
  1. 26/04/16 26/04/16 -
  2. 20/09/21 20/09/21 -
Caricato su

20 settembre 2021

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Bone Metastases NCT02226276

Inglese

Eligibility Bone Metastases NCT02226276

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
women with metastatic her2-positive breast cancers whose disease has progressed on first-line trastuzumab + chemotherapy will be considered eligible for study participation if they meet the following criteria:
Descrizione

Woman Metastatic HER2-positive carcinoma of breast | First line treatment Trastuzumab | Chemotherapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0043210
UMLS CUI [1,2]
C1960398
UMLS CUI [1,3]
C0036525
UMLS CUI [2,1]
C1708063
UMLS CUI [2,2]
C0728747
UMLS CUI [3]
C0392920
participants must be women who have histological confirmation of metastatic invasive breast cancer that has metastasized outside the region of the primary tumor and axilla; biopsy must be obtained within 28 days prior to enrollment; patients must have metastatic disease in lung, liver, soft-tissue or bone to qualify for the study (more than one site is permissible)
Descrizione

Woman Carcinoma breast stage IV | Biopsy | Metastatic Neoplasm Lung | Metastatic Neoplasm Liver | Metastatic Neoplasm soft tissue | Metastatic Neoplasm Skeletal bone

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0043210
UMLS CUI [1,2]
C0278488
UMLS CUI [2]
C0005558
UMLS CUI [3,1]
C2939420
UMLS CUI [3,2]
C0024109
UMLS CUI [4,1]
C2939420
UMLS CUI [4,2]
C0023884
UMLS CUI [5,1]
C2939420
UMLS CUI [5,2]
C0225317
UMLS CUI [6,1]
C2939420
UMLS CUI [6,2]
C0262950
at least 1 site of metastasis >= 20 mm in mean diameter must be identified
Descrizione

Neoplasm Metastasis Site Diameter

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0205145
UMLS CUI [1,3]
C1301886
the cancer must over express her2 as determined by immunohistochemistry (ihc) and/or fluorescence in situ hybridization (fish)
Descrizione

Quantitative HER2 immunohistochemistry (IHC) evaluation of breast cancer | Fluorescent in Situ Hybridization

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3248285
UMLS CUI [2]
C0162789
patients may not have received trastuzumab within 6 weeks of projected 64cu-dota-trastuzumab/pet-ct
Descrizione

trastuzumab | 64Cu-DOTA-trastuzumab | PET/CT scan

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0728747
UMLS CUI [2]
C2745103
UMLS CUI [3]
C1699633
participants must have normal cardiac ejection fraction
Descrizione

Normal cardiac ejection fraction

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3661818
planned therapy with ado-trastuzumab emtansine
Descrizione

Planned Therapeutic procedure ado-trastuzumab emtansine

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1301732
UMLS CUI [1,3]
C2935436
ability to provide informed consent
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
patients that may need dose reduction to commence cycle 1 treatment
Descrizione

Dosage Reduced | Therapeutic procedure

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0178602
UMLS CUI [1,2]
C0392756
UMLS CUI [2]
C0087111
eastern cooperative oncology group (ecog) performance status of 0-2
Descrizione

ECOG Performance Status 0 | ECOG Performance Status 1 | ECOG Performance Status 2

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3830346
UMLS CUI [2]
C3830345
UMLS CUI [3]
C3830344
negative serum pregnancy test (female of childbearing potential only)
Descrizione

Serum pregnancy test negative Female Childbearing Potential

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0430061
UMLS CUI [1,2]
C0086287
UMLS CUI [1,3]
C3831118
patients must have adequate cardiac function; left ventricular ejection fraction (lvef) >= 50% as determined by multi gated acquisition (muga) scan or echocardiogram
Descrizione

Cardiac function | Left ventricular ejection fraction | Multiple gated acquisition scanning | Echocardiography

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0232164
UMLS CUI [2]
C0428772
UMLS CUI [3]
C0521317
UMLS CUI [4]
C0013516
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
participants who have received trastuzumab within the prior 36 days
Descrizione

Received trastuzumab

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514756
UMLS CUI [1,2]
C0728747
participants who are not considered candidates for ado-trastuzumab-emtansine
Descrizione

Not Eligible | ado-trastuzumab emtansine

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1555471
UMLS CUI [2]
C2935436
no metastatic sites >= 20 mm
Descrizione

site, metastatic cancer

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0280457
concurrent malignancy other than skin cancer
Descrizione

Malignant Neoplasm Other | Malignant neoplasm of skin

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0205394
UMLS CUI [2]
C0007114
inability to provide informed consent
Descrizione

Unable Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1299582
UMLS CUI [1,2]
C0021430
Ritorna all'inizio della pagina

Similar models

Eligibility Bone Metastases NCT02226276

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Woman Metastatic HER2-positive carcinoma of breast | First line treatment Trastuzumab | Chemotherapy
Item
women with metastatic her2-positive breast cancers whose disease has progressed on first-line trastuzumab + chemotherapy will be considered eligible for study participation if they meet the following criteria:
boolean
C0043210 (UMLS CUI [1,1])
C1960398 (UMLS CUI [1,2])
C0036525 (UMLS CUI [1,3])
C1708063 (UMLS CUI [2,1])
C0728747 (UMLS CUI [2,2])
C0392920 (UMLS CUI [3])
Woman Carcinoma breast stage IV | Biopsy | Metastatic Neoplasm Lung | Metastatic Neoplasm Liver | Metastatic Neoplasm soft tissue | Metastatic Neoplasm Skeletal bone
Item
participants must be women who have histological confirmation of metastatic invasive breast cancer that has metastasized outside the region of the primary tumor and axilla; biopsy must be obtained within 28 days prior to enrollment; patients must have metastatic disease in lung, liver, soft-tissue or bone to qualify for the study (more than one site is permissible)
boolean
C0043210 (UMLS CUI [1,1])
C0278488 (UMLS CUI [1,2])
C0005558 (UMLS CUI [2])
C2939420 (UMLS CUI [3,1])
C0024109 (UMLS CUI [3,2])
C2939420 (UMLS CUI [4,1])
C0023884 (UMLS CUI [4,2])
C2939420 (UMLS CUI [5,1])
C0225317 (UMLS CUI [5,2])
C2939420 (UMLS CUI [6,1])
C0262950 (UMLS CUI [6,2])
Neoplasm Metastasis Site Diameter
Item
at least 1 site of metastasis >= 20 mm in mean diameter must be identified
boolean
C0027627 (UMLS CUI [1,1])
C0205145 (UMLS CUI [1,2])
C1301886 (UMLS CUI [1,3])
Quantitative HER2 immunohistochemistry (IHC) evaluation of breast cancer | Fluorescent in Situ Hybridization
Item
the cancer must over express her2 as determined by immunohistochemistry (ihc) and/or fluorescence in situ hybridization (fish)
boolean
C3248285 (UMLS CUI [1])
C0162789 (UMLS CUI [2])
trastuzumab | 64Cu-DOTA-trastuzumab | PET/CT scan
Item
patients may not have received trastuzumab within 6 weeks of projected 64cu-dota-trastuzumab/pet-ct
boolean
C0728747 (UMLS CUI [1])
C2745103 (UMLS CUI [2])
C1699633 (UMLS CUI [3])
Normal cardiac ejection fraction
Item
participants must have normal cardiac ejection fraction
boolean
C3661818 (UMLS CUI [1])
Planned Therapeutic procedure ado-trastuzumab emtansine
Item
planned therapy with ado-trastuzumab emtansine
boolean
C0087111 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
C2935436 (UMLS CUI [1,3])
Informed Consent
Item
ability to provide informed consent
boolean
C0021430 (UMLS CUI [1])
Dosage Reduced | Therapeutic procedure
Item
patients that may need dose reduction to commence cycle 1 treatment
boolean
C0178602 (UMLS CUI [1,1])
C0392756 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2])
ECOG Performance Status 0 | ECOG Performance Status 1 | ECOG Performance Status 2
Item
eastern cooperative oncology group (ecog) performance status of 0-2
boolean
C3830346 (UMLS CUI [1])
C3830345 (UMLS CUI [2])
C3830344 (UMLS CUI [3])
Serum pregnancy test negative Female Childbearing Potential
Item
negative serum pregnancy test (female of childbearing potential only)
boolean
C0430061 (UMLS CUI [1,1])
C0086287 (UMLS CUI [1,2])
C3831118 (UMLS CUI [1,3])
Cardiac function | Left ventricular ejection fraction | Multiple gated acquisition scanning | Echocardiography
Item
patients must have adequate cardiac function; left ventricular ejection fraction (lvef) >= 50% as determined by multi gated acquisition (muga) scan or echocardiogram
boolean
C0232164 (UMLS CUI [1])
C0428772 (UMLS CUI [2])
C0521317 (UMLS CUI [3])
C0013516 (UMLS CUI [4])
Item Group
C0680251 (UMLS CUI)
Received trastuzumab
Item
participants who have received trastuzumab within the prior 36 days
boolean
C1514756 (UMLS CUI [1,1])
C0728747 (UMLS CUI [1,2])
Not Eligible | ado-trastuzumab emtansine
Item
participants who are not considered candidates for ado-trastuzumab-emtansine
boolean
C1555471 (UMLS CUI [1])
C2935436 (UMLS CUI [2])
site, metastatic cancer
Item
no metastatic sites >= 20 mm
boolean
C0280457 (UMLS CUI [1])
Malignant Neoplasm Other | Malignant neoplasm of skin
Item
concurrent malignancy other than skin cancer
boolean
C0006826 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0007114 (UMLS CUI [2])
Unable Informed Consent
Item
inability to provide informed consent
boolean
C1299582 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial